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ABSTRACT
We previously reported the potent adverse effects of killer immunoglobulin-like receptor (KIR) ligand mismatch
(KIR-L-MM) on the outcome of T cell–replete unrelated hematopoietic stem cell transplantation (UR-HSCT)
through the Japan Marrow Donor Program. Other UR-HSCT studies have yielded inconsistent results. To ad-
dress this discrepancy, we evaluated candidate factors contributing to the effects of KIR-L-MM on transplanta-
tion outcomes in retrospectively selected hematologic malignancy cases with uniform graft-versus-host disease
(GVHD) prophylaxis (n5 1489). KIR-L-MM in the graft-versus-host direction (KIR-L-MM-G) was associated
with a higher incidence of acute GVHD (aGVHD; P\ .002) and a lower overall survival (OS; P\ .0001) only
without the preadministration of antithymocyte globulin (ATG). Furthermore, in KIR-L-MM-G, the
donor KIR2DS2 gene with the patient cognate C1 ligand was associated with a higher incidence of aGVHD
(P 5 .012). Multivariate analysis by Cox proportional hazard models suggested that donor 2DS2 and ATG pre-
administration were critical factors in grade III-IV aGVHD (hazard ratio 5 1.96; 95% confidence interval 5
1.01-3.80; P5 .045, and hazard ratio5 0.56; 95% confidence interval5 0.31-0.99; P5 .047, respectively). These
results indicate that the adverse effects of KIR-L-MM-G depend on combination of donor-activating KIR geno-
type-patient cognate KIR ligand type and no ATG preadministration, thereby suggesting the importance of
these factors in UR-HSCT and in leukemia treatment using natural killer (NK) cell alloreactivity.
 2008 American Society for Blood and Marrow TransplantationINTRODUCTION
Natural killer (NK) cell alloreactivity plays an im-
portant role in hematopoietic stem cell transplantation
(HSCT,) and its therapeutic use in leukemia treatment
has been considered because of its possible graft-ver-
sus-leukemia (GVL) effect [1]. The beneficial effects
of NK cell receptor killer immunoglobulin-like recep-tor (KIR) ligand incompatibility between patient and
donor in the HLA-mismatched related hematopoietic
stem cell transplantation (R-HSCT) has been reported
[2,3]. These effects in unrelated hematopoietic stem
cell transplantation (UR-HSCT) have been controver-
sial, however [4]. We recently reported the potent ad-
verse effects of HLA-C-KIR ligand incompatibility75
76 T. Yabe et al.(ligand–ligand analysis) in unrelated T cell–replete
HLA-A, -B, and -DR serologically matched bone mar-
row transplantation without preadministration of an-
tithymocyte globulin (ATG) (n 5 1790) through the
Japan Marrow Donor Program (JMDP) [5]. Other
UR-HSCT studies have documented either adverse
or beneficial effects of KIR ligand incompatibility on
transplantation outcome [6-14].
Candidate factors possibly accounting for this dis-
crepancy include T cell depletion, KIR genotype of
patients and donors, sample size, ethnicity, number
and source of stem cells, ATG preadministration,
graft-versus-host disease (GVHD) prophylaxis, and
diseases. Associations between KIR genotype and
clinical outcome have been reported in both related
HLA-identical transplantation [15-22] and unrelated
transplantation settings [10,23-27]. However, the con-
tribution of the KIR genotype to KIR ligand compati-
bility has not yet been well defined. Preadministration
of ATG in the conditioning regimen both reduces
stem cell rejection by host lymphocytes and prevents
GVHD by donor-derived lymphocytes, as the drug re-
mains in the patient’s blood for several weeks after
transplantation and affects residual donor mature lym-
phocyte activity and reconstitution of the lymphocyte
repertoire from donor stem cells [28]. Earlier UR-
HSCT studies have demonstrated the need for ATG
administration to gain the beneficial effect of NK
cell alloreactivity [7], whereas an adverse effect of
KIR-L-MM has been reported in both a non-ATG
preadministration study [6] and ATG preadministra-
tion studies [8,9]; however, a direct comparison of
the ATG-administration and ATG-nonadministra-
tion groups in a single large cohort has never been per-
formed. Such a study is desirable for a precise
evaluation of the effect of ATG on KIR-L-MM.
In this study, patients with hematologic malig-
nancy cases who received uniformGVHD prophylaxis
were retrospectively selected from patients undergo-
ing unrelated bone marrow transplantation through
the JMDP. All cases were HLA-A, -B, and -DR sero-
logically matched (ie, including HLA-A, -B, and -DR
allele-mismatched pairs as well as HLA-Bw4 and
HLA-A3 and -A11 KIR ligand matched and HLA-
C-KIR ligand matched and mismatched pairs) and
mostly uniform with regard to ethnicity and transplan-
tation regimens [29,30]. In these cases, the effects of
KIR genotype, KIR ligand compatibility, and ATG ad-
ministration status on transplantation outcomes were
analyzed to resolve the discrepant findings regarding
the effects of KIR-L-MM.
PATIENTS AND METHODS
Patient and Cohort Selection Criteria
A cohort (n 5 1489) was selected from among
patients undergoing unrelated bone marrow trans-plantation between 1993 and 2000 through the
JMDP. Characteristics of the patients and donors are
summarized in Table 1. A source of hematopoietic
stem cells of all transplantations were from T cell–
replete and HLA-A, -B, and -DR serologically
matched bone marrow. Patients with hematologic ma-
lignancies, including 401 cases of acute myelogenous
leukemia (AML), 438 cases of acute lymphoblastic leu-
kemia (ALL), 451 cases of chronic myelogenous leuke-
mia (CML), 137 cases of myelodysplastic syndrome
(MDS), and 62 cases of malignant lymphoma (non-
Hodgkin lymphoma) were analyzed. GVHD prophy-
laxis other than the combination of cyclosporine and
short-term methotexate (the most common treatment
reported in the JMDP [68.1%]) was excluded. Ninety-
four patients with preadministered ATG were in-
cluded and analyzed separately or together with the
nonadministered cases. Standard risk for relapse was
defined as the status of first complete remission (CR)
of AML or ALL, first chronic phase (CP) of CML at
transplantation, or refractory anemia (RA) in MDS.
High risk was defined as a more advanced status than
standard risk in AML, ALL, CML, and MDS. All pa-
tients were preconditioned with a myeloablative regi-
men, and 1204 patients received total body
irradiation (TBI)-containing regimens, whereas 285
received non–TBI-containing regimens. The final
clinical survey of these patients was performed as of
Table 1. Patient characteristics and matching of HLA allele between
patient and donor
C-mismatch
All
patients
C-
match
KIR-L-
MM-G
KIR-
L-M
Analyzed number 1489 1013 81 395
AML 401 286 17 98
ALL 438 306 24 108
CML 451 296 25 130
MDS 137 82 14 41
Malignant lymphoma 62 43 1 18
Patient age 26 27 25 27
Donor age (90 high risk) 34 35 35 34
Sex match 57 56.6 59.3 57.5
TBI 80.9 81 79 80.8
Status of leukemia
(% high risk)
55.1 53.5 70 56
HLA-allele mismatch, %
A 18.5 14.2 28.4 27.6
B 9.1 3.5 25.9 20.1
C 32 0 100 100
DRB1 18.9 15.5 32.1 24.8
DQB1 22 18.7 28.4 29.1
DPB1 71.3 74.8 82.7 76.7
ATG1 94 56 11 27
ATG2 1395 957 70 368
Donor KIR 2DS2
analyzed
233 83 80 70
Patient–donor
16 KIR type analyzed
187 70 55 62
Effect of KIR Genotype and ATG on Transplantation Outcome 77June 1, 2005. The mean and range for clinical follow-
up were 2914 days and 1639-4597 days, respectively. A
part of the subject population (leukemia treated with
cyclosporine and short-term methotexate; n 5 1210)
was overlapped with that reported in our previous
study [5]. Written informed consent was obtained
from all patients and donors, and the study design
was approved by the institutional review boards of
the Japanese Red Cross Tokyo Metropolitan Blood
Center, the Aichi Cancer Center, and the JMDP.
HLA and KIR Ligand Typing and Compatibility
Characterization of Patient–Donor Pairs
HLA-A, -B, -C, -DR, -DQ, and -DP alleles of all pa-
tients and donors were retrospectively determined by
DNA typing as described previously [5]. For analysis
of GVHD and leukemia relapse, HLA allele mismatch
among donor–patient pairs was defined as the patient’s
alleles not being shared by the donor. KIR ligand spec-
ificity of the HLA-C antigen was determined accord-
ing to the amino acid residues of the HLA-C allele.
C1 ligand specificity consists of Asn 80 (Cw1, w3,
w7, w8, and others); C2 specificity consists of Lys 80
(Cw2, w4, w5, w6, and others). In the cohort (patients
and donors, n 5 2978), the numbers of C1C1, C1C2,
and C2C2 were 2555 (85.8%), 399 (13.4%), and 24
(0.81%), respectively. HLA-C mismatched pairs
(n 5 476) were divided into KIR ligand mismatch in
the GVH direction (KIR-L-MM-G) (n 5 81) and
KIR ligand match in the GVH direction (KIR-L-M)
(n 5 395). KIR-L-MM-G was defined as the donor’s
KIR ligand for HLA-C not being shared by the pa-
tient’s ligand. KIR-L-M included ligand match and li-
gand mismatch in the host-versus-graft (HVG)
rejection direction. The combinations of KIR ligands
in KIR-L-MM-G were as follows: C1C1 (patient)–
C1C2 (donor), 78 (96.2%); C2C2–C1C2, 1 (1.2%);
C1C1–C2C2, 2 (2.5%); and C2C2–C1C1, 0.
KIR Genotyping and Profile Analysis
KIR genotyping was performed using genomic
DNA from patient and donor, and the presence of
the 16 KIR genes (2DL1, 2DL2, 2DL3, 2DL4, 2DL5,
2DS1, 2DS2, 2DS3, 2DS4, 2DS5, 3DL1, 3DL2,
3DL3, 3DS1, 2DP1, and 3DP1) was determined by
the polymerase chain reaction sequence-specific
primer (PCR-SSP) method [31] with minor modifica-
tions [32]. Pairs of all of KIR-L-MM-G (n5 81) cases
and also KIR-L-M from HLA-C mismatch cases were
selected, and HLA-C–matched cases were randomly
selected as controls for the comparison. From the 260
pairs analyzed, all 16KIR types of both patients and do-
nors were successfully obtained in only 187 pairs, be-
cause of either insufficient quantity or quality of
DNA. These data were used for evaluating KIR gene
frequency and performing statistical analyses (Table
1). For the KIR-L-MM-G donor 2DS2 analysis, 46cases, in which donor 2DS2 status was obtained, were
added (for a total of 233 cases). KIR haplotype A is de-
fined as carrying a single activating KIR gene, 2DS4;
KIR haplotype B has additional activating KIR genes
[33].
Definition of Transplantation-Related Events
The occurrence of acute GVHD (aGVHD) was
evaluated according to grading criteria in patients
who survived for more than 8 days after transplanta-
tion, as described previously [30].
Statistical Analysis
Statistical analysis was performed as described pre-
viously [5]. All analyses were conducted using STATA
version 8.2 (STATA Corp, College Station, TX).
Overall survival (OS) rate was assessed using the
Kaplan-Meier product limit method. Cumulative inci-
dence of aGVHD and leukemia relapse were assessed
as described previously [5] to eliminate the effects of
competing risks. The competing events regarding
aGVHD and relapse were defined as death without
aGVHD and death in remission (treatment related
mortality), respectively. For each endpoint, a log-
rank test was applied to assess the impact of the factor
of interest. Multivariate analysis by Cox proportional
hazard models was applied to assess the impact of
KIR ligand compatibility, donor KIR genotype, and
ATG administration along with potential con-
founders. Confounders considered were HLA-A, -B,
-DR, -DQ, and -DP matching (GVH direction), sex
(donor–patient pairs), patient age (linear), donor age
(linear), type of disease, risk of leukemia relapse (stan-
dard and high, leukemia only analyzed), number of
cells transplanted (linear), and preconditioning (TBI
vs non-TBI). The number of nucleated cells before
the manipulation of bone marrow was replaced with
the number of cells transplanted. P values\ .05 were
considered statistically significant. Adjustment of P
values for multiple comparison was done because of
an a priori hypothesis that activating KIR would inter-
act with the cognate ligand and transduce a stimulatory
signal only when the inhibitory signal was inactive.
RESULTS
Adverse Effects of KIR Ligand Incompatibility
We first confirmed the effects of KIR-L-MM in
the newly selected cohort in this study (Table 1).
The cumulative incidence of aGVHD and OS are
shown in Figure 1. KIR-L-MM-G showed a signifi-
cantly higher incidence of grade III-IV aGVHD
(41.1%;95%confidence interval [CI]529.5%-51.9%)
compared with KIR-L-M in HLA-C–mismatched
patients (29.7%; 95% CI 5 25.2%-34.3%; P 5
.032). A similar trend was seen in grade
II-IV aGVHD (data not shown). In addition, in
78 T. Yabe et al.Figure 1. Effects of KIR ligand mismatch on transplantation outcome. Cumulative incidence of acute GVHD (grade III-
IV) (A) and overall survival (B) bymatching of KIR ligands in theGVHDdirection. The directions of HLA-Cmismatching
were GVH and/or HVG. All patients were analyzed. The solid line represents HLA-C match (CM), the thin dotted line
represents HLA-Cmismatch KIR ligand match in the GVHD direction (C-MMKIR-L-M), and the thick dotted line rep-
resents HLA-Cmismatch KIR ligand mismatch in the GVH direction (C-MMKIR-L-MM-G). The log-rank test was ap-
plied between CMM KIR-L-MM-G and CMM KIR-L-M.
Table 2. Multivariate analysis of the effects of KIR ligand matching, donor KIR genotype, and ATG preadministration
Group Confounders
Subject
number
aGVHD 3-4 aGVHD 2-4 Relapse OS
HR (95%CI)
P
value HR (95%CI)
P
value HR (95%CI)
P
value HR (95%CI)
P
value
A HLA-C (HCX) matched 1013 1.00(reference) 1.00(reference) 1.00(reference) 1.00(reference)
HLA-C-MM (HCX)
and KIR-L-MM-G
81 3.08(2.05-4.62) \.001 1.76(1.28-2.43) .001 1.27(0.73-2.22) .403 1.93(1.47-2.53) \.001
HLA-C-MM (HCX)
and KIR-L-M
395 2.00(1.54-2.61) \.001 1.47(1.23-1.77) \.001 0.58(0.41-0.81) .001 1.17(0.99-1.37) .065
ATG (yes vs no) 94 vs 1395 0.56(0.31-0.99) .047 0.63(0.43-0.93) .019 1.01(0.60-1.71) .957 1.23(0.92-1.65) .158
B KIR-L (MM-G vs M) 80 vs 70 1.36(0.76-2.44) .304 1.32(0.81-2.15) .258 2.16(0.89-5.24) .087 1.60(1.05-2.44) .027
Donor KIR
genotype (2DS2 1 vs 2)
28 vs 122 1.96(1.01-3.80) .045 1.62(0.92-2.85) .095 0.78(0.24-2.47) .666 1.04(0.62-1.74) .889
Adjusted for HLA-A, -B, -DR –DQ, DP(GVH direction), age, donor age, donor-recipient sex pattern, disease, TBI, and risk.
Group A: all pairs, n51489; group B: HLA-C-mismatched and donor 2DS2-typed n5150.HLA-C–mismatched patients, KIR-L-MM-G had
a lower 5-year OS rate (23.2%; 95% CI 5 14.6%-
32.9%) than KIR-L-M (41.8%; 95% CI 5 36.9%-
46.7%; P \ .0001). Multivariate analysis (Table 2,
group A [n 5 1489]) also demonstrated the strong
adverse effects of KIR-L-MM-G in HLA-C mis-
match on aGVHD (grade III-IV GVHD: hazard
rate [HR] 5 3.08, P \ .001; grade II-IV GVHD:
HR5 1.76, P5 .001) and on OS (HR5 1.93; P\ .001),
but not on relapse (HR 5 1.27; P 5 .40). Allele
mismatches of HLA-A, -B, -DR, -DQ, and -DP loci
of the patient and donor were considered con-
founders in the analysis; consequently, the observed
KIR-L-MM-G effects in HLA-C mismatch were
adjusted for other HLA disparities. These adverse
effects of KIR-L-MM-G on aGVHD and OS were
consistent with those found in our previous study
[5]. Consequently, we further analyzed the factors
responsible for the effects of KIR-L-MM-G on
transplantation outcome using this cohort.KIR Genotypes and Profiles of Patients and Donors
The selected patients and donors were analyzed
using the PCR-SSP method for genotyping 16 differ-
ent KIR genes. Data for 187 pairs were obtained, in-
cluding 55 cases of KIR-L-MM-G and 62 cases of
KIR-L-M in HLA-C mismatch and 70 cases of
HLA-C match (Table 1). Table 3 shows the frequency
of each KIR gene and the KIR profiles of patients and
donors, demonstrating no significant differences be-
tween the patients and donors. The frequency of
each KIR was similar to that of the healthy Japanese
population [32-34]. Nearly half of the patients had
only haplotype A.
Donor KIR2DS2 Exacerbated aGVHD in
KIR-L-MM-G
To statistically evaluate the possible involvement
of KIR genotype in the adverse effects of KIR-L-
MM-G, we investigated the particular combinatory
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e.effects of donorKIR genotype and patient cognate KIR
ligand type (receptor-ligand analysis). For the inhibi-
tory KIR, we attempted to examine the combination
of a particular ligand in the patient and absence of
the cognate inhibitory KIR gene in the donor. But
with regard to HLA-C-KIR ligand specificity, almost
all individuals were positive for both C1 and C2 inhib-
itory KIRs (2DL2 and/or 2DL3, and 2DL1, respec-
tively; Table 3); therefore, there was no mismatch
between patient KIR ligand and donor inhibitory
KIR genotype combination or vice versa. In contrast,
activating KIR genotypes were quite variable among
individuals, and mismatch (ie, reactive) combinations
of activating KIR with its presumed ligand (2DS1
with C2 and 2DS2with C1, respectively) were present.
For activating KIR, the combination of a particular
ligand in the patient and presence of the cognate-acti-
vating KIR but absence of the corresponding inhibi-
tory KIR in the donor was selected and analyzed.
This choice was based on dominance of the inhibitory
signal over the cognate-activating signal [35,36]. The
corresponding activating donor KIR genotypes to pa-
tients C1C1 and C2C2 in KIR-L-MM-G were 2DS2
and 2DS1, respectively. However, the frequency of
C2C2 in the JMDP cases was too low (only 1 case in
this study) to permit statistical evaluation. As shown
in Figure 2, donor 2DS2-positive cases in KIR-L-
MM-G had a significantly higher incidence of aGVHD
(grade III-IV GVHD, 70.9% [95% CI 5 40.0%-
87.9%]; grade II-IV GVHD, 78.6% [95% CI 5
47.2%-92.5%]) compared with the donor 2DS2-nega-
tive cases (grade III-IV GVHD, 33.6% [95% CI 5
22.0%-45.7%]; grade II-IV GVHD, 54.4% [95%
CI 5 40.8%-66.1%]; P 5 .012 and .029, respectively).
This was not true for KIR-L-M cases, however. These
results suggest that the adverse effects of KIR-L-MM-
G depend on combinations of the donor-activating
KIR genotype and cognate patient ligand C1.
To explore the possibility of the neighboring acti-
vating KIR loci being the primary factor in outcomes
because of possible linkage disequilibrium, we next
investigated the associations between other KIR geno-
types and transplantation outcomes. No other activat-
ing KIR, but inhibitory 2DL2 (located adjacent to and
tightly linked with 2DS2) showed a significant associ-
ation with the incidence of aGVHD (data not shown).
No significant associations between donor 2DS2 with
relapse or OS in KIR-L-MM-G could be observed
(Figures 2C and D, respectively).
Multivariate analysis (Table 2; group B [n 5 150])
demonstrated that the donor 2DS2 was a possible risk
factor for grade III-IV aGVHD in HLA-C–mis-
matched cases (HR5 1.96; P5 .045). The same trend
was observed for grade II-IV GVHD (HR5 1.62; P5
.095).We also tested the currently proposed model for
the KIR genotype effects on HSCT outcomes (donor
KIR gene numbers [10,16,18,26,37], comparison of
80 T. Yabe et al.Figure 2. Effects of donor KIR2DS2 in KIR ligand mismatch on transplantation outcome: Cumulative incidence of
aGVHD, relapse, and overall survival with presence or absence of donor KIR2DS2 gene in HLA-C–mismatched patients.
Grade III-IVGVHD (A and E), grade 2-4GVHD (B and F), relapse (C andG), and overall survival (D andH) with KIR-L-
MM-G (A-D) or KIR-L-M (E-H) cases were analyzed. The solid line represents donor KIR2DS2-positive; the dotted line,
donor KIR2DS2-negative.KIR genotype and profile between patient and
donor [receptor–receptor analysis] [17,19,25], com-
patibility score [24], ligand homozygosity in pa-
tients [21,27,38,39], and ‘‘missing ligand’’ effect
[3,11,13,40,41]), and found no significant associations
in this cohort (data not shown).
ATG Preadministration Ameliorates the Adverse
Effects of KIR-L-MM-G on aGVHD and OS
In our previous study [5], the incidence of aGVHD
was high in KIR-L-MM-G, where all cases did not in-volve ATG administration in the conditioning regi-
men, which is common in the JMDP cases. In the
present study, we included rare ATG-administered
cases (n 5 94) in the analysis and evaluated the effects
of ATG administration on KIR-L-MM-G. We found
no significant differences in most of the parameters be-
tween the ATG-administered and non–ATG-adminis-
tered groups, except for patient average age (18 years vs
27 years). Multivariate analysis (Table 2; group A [n5
1489]) indicated that ATG administration was a risk-
reducing factor for severe aGVHD (grade III-IV
Effect of KIR Genotype and ATG on Transplantation Outcome 81Figure 3.Effects of ATG preadministration in KIR ligandmismatch on transplantation outcome: Cumulative incidence of
aGVHD, relapse, and overall survival of patients not receiving ATG (A-C) and those receiving ATG (D-F). The solid line
represents HLA-C match (C-M), the thick dotted line represents HLA-C mismatch KIR ligand match in the GVHD di-
rection (C-MM KIR-L-M), and the thin dotted line represents HLA-C mismatch KIR ligand mismatch in the GVH di-
rection (C-MM KIR-L-MM-G). The log-rank test was applied between CMM KIR-L-MM-G and CMM KIR-L-M.GVHD: HR 5 0.56; P 5 .047; grade II-IV GVHD:
HR 5 0.63, P 5 .019), whereas no significant effects
on relapse or OS could be seen.
The cumulative incidence of aGVHDwas assessed
separately in the non–ATG-administered and ATG-
administered groups (Figures 3A and 3D, respec-
tively). In the non–ATG-administered group, the
incidence of grade III-IV GVHD was significantly
higher in KIR-L-MM-G than in KIR-L-M (47.7%
[95% CI 5 35.2%-59.2%] vs 29.4% [95%
CI524.8%-34.1%]; P5 .0014), as found in our previ-
ous study [5]. In contrast, no grade III-IV aGVHDwas
observed in KIR-L-MM-G cases in the ATG-admin-
istered group (2 cases of grade 2, 2 cases of grade 1,
and 7 cases of grade 0), and the preventive effects of
KIR-L-MM-G on severe aGVHD were significant
(P 5 .042) although only a small number were ana-
lyzed (n 5 38). We analyzed the effects of 2DS2 inthe non–ATG-administered cases. In KIR-L-MM-G,
the incidence of grade III-IV aGVHD was signifi-
cantly higher in the donor 2DS2-positive cases (n 5
15) than in the donor 2DS2-negative cases (n 5 54)
(76.4% [95% CI 5 43.5-91.7%] vs 40.1% [95%
CI 5 26.5%-53.2%]; P 5 .048), suggesting that the
adverse effects of donor 2DS2 are independent of
ATG administration. In ATG-administered cases,
no grade III-IV aGVHD was observed in donor
2DS2-negative KIR-L-MM-G (n 5 15); in 1 donor
2DS2-positive KIR-L-MM-G case, the patient failed
engraftment but showed no aGVHD, and died on
day 35. Therefore, we could not statistically evaluate
the effect of ATG on the 2DS2-positive cases.
As shown in Figure 3B, in non–ATG-administered
cases, the cumulative incidence of relapse was higher in
KIR-L-MM-G than in KIR-L-M (16.1% [95% CI 5
8.6%-25.8%] vs 11.9% [95% CI 5 8.9%-15.3%];
82 T. Yabe et al.P 5 .046), which was seen mainly in ALL (data not
shown), as was found in our previous study [5]. In con-
trast, no significant increase in relapse was obtained in
ATG-administered cases (P5 .082) (Figure 3E). As in
our previous study [5], in non–ATG-administered
cases, overall survival rate was significantly lower in
KIR-L-MM-G than in KIR-L-M (21.0% [95% CI 5
12.2%-31.3%] vs 42.0% [95% CI 536.8%-47.0%];
P\ .0001) (Figure 3C). On the other hand, in ATG-
administered cases, no significant difference was ob-
served between KIR-L-MM-G and KIR-L-M
(36.4% [95% CI 5 11.2%-62.7%] vs 39.5% [95%
CI5 21.2%-57.3%]; P5 .79) (Figure 3F), suggesting
that ATG preadministration in the conditioning regi-
men abolished the adverse effect of KIR-L-MM-G on
survival.
DISCUSSION
In the present study, we identified donor KIR
genotype–patient KIR ligand combination and no
ATG preadministration as critical factors for the ad-
verse effects of KIR-L-MM-G on transplantation out-
comes in the JMDP. The cases analyzed in this study
were all HLA-A, -B, and -DR serologically matched;
thus, we were able to evaluate the HLA-C ligand com-
patibility effects, because the HLA-Bw4 and HLA-A3
and -A11 KIR ligands were all matched. Other groups
included mostly Bw4 ligand mismatch cases in KIR-L-
MM-G analysis [2,6,7,10-12,14,21,42]. The Bw4 (pa-
tient) -3DL1 (or -3DS1) (donor) combinatory effect
also may affect transplantation outcome.
In the KIR-L-MM-G combination, the patient
lacks the donor’s KIR ligand. In this situation, donor
NK cells may react with the patient cells according
to the ‘‘missing self’’ model [43]. Previous KIR ligand
compatibility data, together with the present data,
confirm that the KIR-L-MM-G has potent adverse ef-
fects on UR-HSCT. In most KIR-L-MM-G cases in
the JMDP, the donor and patient ligand types are
C1C2 and C1C1, respectively, suggesting that C1C2
donor NK cells (and/or some T cells) respond to
C1C1 patient cells. In this case, donor NK cells lack
the inhibitory KIR for C1 (2DL2 and 2DL3) in terms
of genotype or phenotype, or both. As shown in the
present results, almost all JMDP donors examined
posessed an inhibitory KIR gene for C1 (2DL3). The
subpopulation of donor NK cells thus appears to lack
cell surface expression of the C1-inhibitory KIR mol-
ecule, despite the presence of the genes. This is ex-
plained by the ‘‘at least one inhibitory receptor
expression’’ model [44], in which each NK cell must
express 1 inhibitory receptor for the self–major histo-
compatibility complex (MHC) class I to avoid autor-
eactivity, but expression of other receptors is
‘‘stochastic.’’ Consequently, NK cell subpopulations
lacking the C1-inhibitory KIR (2DL2 and 2DL3) buthaving the C2-inhibitory KIR (2DL1) would react
with C1C1 (C2-lacking) patient cells. Therefore, the
donor inhibitory KIR repertoire at the expression
level, not at the genomic level, appears to influence
outcome in the JMDP. The importance of the inhibi-
tory KIR expression repertoire and functional analysis
of donorNK cells has been discussed previously [3,45].
With a lack of inhibitory KIR signals, NK cells re-
spond to target cells through activation signals from
activating receptors. 2DS1 and 2DS2 are assigned to
recognize C2 andC1, respectively, but other activating
KIR ligand specificities (2DS3-5 and 3DS1) are un-
identified [35]. Therefore, we were able to evaluate
only these 2 KIRs for combinatory effects with their li-
gands. As described in Results, a higher incidence of
severe aGVHD was observed in the 2DS2-positive
donors in the KIR-L-MM-G cases, but not in the
KIR-L-M cases. This suggests that 2DS2-positive
lymphocytes (NK cells and/or some T cells) react
with cognate ligand (C1)-positive cells and exacerbate
aGVHD. Recently, La Nasa et al.[27] reported that
the patient KIR ligand homozygosity, but not donor
KIR genotype, is predictive for the outcome of
HLA-matched UR-HCT in patients with beta-thalas-
semia. Their cases were all KIR ligand-matched trans-
plantation and the donor-activating KIR–patient
cognate ligand combination had no significant effect
on the outcomes. Their results are consistent with
our findings indicating that the donor 2DS2–patient
C1 combination of ligand-matched pairs has no effect
on any outcomes (Figure 2E-H). This is in accordance
with the notion that an activatingKIRworks only when
the patient has the cognate ligand and that the donor
inhibitory KIR does not function (Fig. 4). Chewning
et al [36] reported thatKIR2DS1-positiveNKcells rec-
ognized C2-expressing target cells and showed allor-
eactivity in vitro supporting the concept of this model.
Although adverse impacts of donor 2DS2 on trans-
plantation outcome have been documented previously
[15,18,23], the present study is the first report on the
adverse effects of the 2DS2–cognate ligand C1 combi-
nation on aGVHD incidence. Because we had an a pri-
ori hypothesis, we did not apply adjustment of P-value
in our analysis; however, our results must be inter-
preted with caution. KIR-L-MM-G is infrequent in
the JMDP (only 81 of 1489 cases in the present study),
and the frequency of 2DS2 is low in Japan [32,33], and
confirmation in other independent cohorts from dif-
ferent populations will support our findings. Combi-
natory effects of 2DS2 and cognate ligand C1 also
have been reported in disease susceptibility studies, in-
cluding studies of type I diabetes mellitus [46], ulcera-
tive colitis [47], rheumatoid vasculitis [48], and
tuberculosis [49]. Furthermore, extensive genetic
analysis of KIR and HLA genotypes of various ethnic
populations have demonstrated a strong negative cor-
relation of activating KIR and its putative ligand
Effect of KIR Genotype and ATG on Transplantation Outcome 83Figure 4. Model of interaction between activating KIR and cognate KIR ligand. Donor-activating KIR transduces an ac-
tivating signal on recognition of the cognate KIR ligand of the patient cell in KIR-L-MM-G case (B). The activating signal
is canceled by an inhibitory signal from inhibitory KIR, which recognizes the KIR ligand of the patient cell in KIR-L-M
case (D).combination including 2DS2–C1, suggesting coevolu-
tion of the activating receptor–ligand loci [50]. Taken
together with our data, these clinical and population
genetic studies suggest a direct receptor–ligand inter-
action between 2DS2 and C1; however, binding stud-
ies using soluble 2DS2 molecules have shown no or
a very weak binding to C1molecules or C1-transfected
cells, challenging the notion of C1 as a 2DS2 ligand
[51-53]. Recombinant 2DS1 also showed very low or
no affinity to C2 [54]. This disparity may be linked
to differences in the nature of ligand binding between
inhibiting and activating receptors. One possible fac-
tor is class I-binding peptides. The peptide-dependent
binding with class I-binding receptors is recognized in
most of the inhibitory receptors [53,55-58] and also
has been suggested in activating KIR [53,58,59]. The
peptide repertoire that allows strong KIR binding
might be more restricted in activating KIR cases than
in inhibitory ones. Alternatively, activating KIR–li-
gand binding may be somehow strengthened under
stress conditions, such as transplantation or viral infec-
tion. Epstein Barr virus–transformed C1-positive cells
were found to be stained slightly by recombinant 2DS2
tetramers [53]. A mutation study found that only 1
amino acid substitution in 2DS2 increased its level of
binding to C1 to that of inhibitory 2DL2, suggesting
that a very fine conformational microstructure change
controls KIR binding specificity [60].
Inhibitory 2DL2 also showed a significant associa-
tion with the incidence of severe aGVHD.Thismay besecondary to the 2DS2–C1 association [50]; alterna-
tively, donor 2DL2-positiveNK cells might have a dif-
ferent effect than 2DL3-positive NK cells on acute
GVHD incidence, because the binding affinity to C1
is higher in 2DL2 than in 2DL3 [60]. Other groups
have analyzed activating KIR gene number and out-
come and have reported both beneficial and adverse
associations [10,16,26,37]. We did not find such
quantitative KIR loci effects in this JMDP cohort
(data not shown); KIR genotype variation among
various ethnic groups may be responsible for these
differences.
Preadministration of ATG to a patient is also a crit-
ical factor in attenuating the adverse effects of KIR-L-
MM-G on transplantation outcome. Our findings
demonstrate that KIR-L-MM-G had potent adverse
effects (higher aGVHD incidence and lower OS) with-
out ATG administration, and that ATG administra-
tion in the conditioning regimen ameliorated most of
these adverse effects. Although the average patient
age in the ATG-administered group was about 10
years younger than that in the non–ATG-administered
group in this study, multivariate analysis including age
as a confounder also identified the ATG effect as an
independent factor for incidence of aGVHD (see
Table 2). To the best of our knowledge, this is the first
direct comparison UR-HSCT study on the effects of
ATG preadministration under the same transplanta-
tion regimen with similar genetic backgrounds.
Because far fewer ATG-administrated cases than
84 T. Yabe et al.non–ATG-administered cases are included in the
JMDP (an imbalance that could bias statistical results),
further evaluation of large numbers of ATG-preadmi-
nistered cases indifferent ethnic populations areneeded.
Administration of ATG extensively depletes pa-
tient and donor T cells, thus strongly inhibiting the re-
sponses of alloreactive T cells. Because the JMDP
cases are all unmanipulatedT cell–replete marrow, do-
nor alloreactive T cell response may be very strong,
which would obscure some of the NK cell beneficial
effects [61]. In KIR-L-MM-G without ATG preadmi-
nistration, alloreactive NK cells were activated by
2DS2–C1 interaction without inhibitory KIR signals
and may have augmented alloreactive donor T cell re-
sponses, resulting in increased aGVHD incidence and
mortality. Alternatively, KIR-positive T cells may have
been responsible for inducing aGVHD. In contrast,
with ATG preadministration, donor T cells are largely
depleted, and the beneficial effects of NK cell alloreac-
tivity on aGVHD incidence may become prominent.
Too few ATG-treated cases were analyzed (n 5 11)
to allow confirmation of the preventive effects of
KIR-L-MM-G on acute GVHD, but the results
are consistent with those for the HLA haplo-mis-
matched, ATG-preadministered R-HSCT [2]. In
mouse GVHD models, alloreactive NK cells pre-
vented donor alloreactive T cell stimulation and
suppressed aGHVD by lysing donor antigen-present-
ing cells [2]. These mechanisms might explain the pre-
ventive effects of KIR-L-MM-G on the incidence of
aGVHD. NK cell reconstitution after transplantation
might be influenced by ATG treatment as well as by
KIR ligand and KIR genotype variability [39,62,63].
Our data suggest that the KIR-L-MM-G combination
must be avoided in JMDP transplantation unless ATG
is used in the conditioning regimen.
Another possible factor is mismatch combination
dissimilarity resulting from genetic variability in
HLA and KIR in populations with different ethnic
backgrounds. There are allele frequency differences
in HLA-C among human populations in terms of the
HLA-C KIR ligand [50]. Because the C1 ligand type
is dominant in the Japanese population (allele fre-
quency 0.92), KIR-L-MM-G is relatively rare (5%)
compared with the incidence in White populations.
Furthermore, in the KIR-L-MM-G, the C1C1 (pa-
tient)–C1C2 (donor) combination is common (95%)
[5]. Therefore, we could focus on the KIR ligand
incompatibility and the 2DS2 effects on the C1-homo-
zygous patients in this study. In contrast, the White
population more frequently exhibits the C2 type
[50]. Consequently, the KIR-L-MM-G frequency is
higher in Caucasian than Japanese and might include
C2C2 (patient)–C1C2 (donor), C2C2–C1C1, and
C1C1–C2C2 combinations, in addition to the
C1C1–C1C2 combination. Therefore, not only
the C1C1 (patient)–2DS2 (donor) combination, butalso the C2C2 (patient)–2DS1 (donor) combination,
might contribute considerably to the effects of KIR-
L-MM-G in White [36]. The inhibitory capacity of
C1 is reportedly weaker than that of C2 [64], and the
binding strength of inhibitory KIR to the ligand
HLA-C is different as well (2DL1 . 2DL2 . 2DL3)
[60]. There may be more variability in inhibitory path-
ways in White populations; indeed, several groups
have reported that the transplantation outcomes vary
between C1-homozyous and C2-homozygous patients
[15,19,38,39]. KIR genotype also shows ethnic vari-
ability [33,50]; Japanese have a markedly high fre-
quency of the A haplotype and a very low frequency
of 2DS2 (16% in the JMDP, compared with a fre-
quency of. 40% in most Caucasian and African pop-
ulations). One potential factor not examined in the
present study is KIR allelic polymorphism. Yawata
et al. [34] have shown that allelic polymorphism mod-
ulates the level and frequency of KIR3D expression, as
well as its inhibitory capacity. These allelic differences
might influence outcomes even though HLA-A- and
B-KIR ligand specificities were the same in donors
and recipients in the present study.
Here we found that the combination of donor-
activating KIR genotype–patient cognate KIR ligand
type and ATG administration in the conditioning reg-
imen were critical factors in the adverse effects of KIR-
L-MM-G on transplantation outcome. Alloreactivity
ofNK cells may be either beneficial or adverse depend-
ing on the above factors. However, other important
parameters also may contribute to transplantation out-
come. Further large-scale international collaborative
studies, including a variety of ethnic populations and
statistical comparisons under uniform regimens, are
needed to gain further insight into the effects of NK
cell alloreactivity on transplantation and to guide the
development of cell therapy using alloreactive NK
cells for leukemia and other diseases.
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